The Clinical Research Team at True You Weight Loss is dedicated to advancing patient care through hypothesis-driven inquiry, rigorous studies, and peer-reviewed data. The latest innovation in bariatric endoscopy is GFMA (gastric fundal mucosal ablation). Discover how True You Weight Loss is pioneering this technique to provide new minimally-invasive weight loss options for our patients.
Ghrelin production was decreased by 40-50% in both the tissue of the stomach and in the bloodstream by 3 months after the procedure. This offers similar benefits to a surgical sleeve (sleeve gastrectomy), where the fundus is surgically removed - all without the risks or side effects of surgery. Ghrelin levels remained low over the next year.
After GFMA, patients’ stomach capacity decreased by 45%. This is because the ablation causes the fundus to contract and scar down, reducing the size of the stomach.
After GFMA, patients’ hunger and cravings decreased, and their confidence in their ability to resist overeating increased.
In the six months following GFMA, patients lost an average of 20 lbs.
GFMA has proven to be a safe and effective technique; in our two separate clinical trials of GFMA, there were zero complications. Because there is a theoretical risk of stomach ulcer, GMFA is accompanied by 12 weeks of anti-ulcer medication and avoidance of non-steroidal anti-inflammatory drugs (e.g., ibuprofen, naproxen, meloxicam).
If you are interested in learning more about GFMA and its role in our program, please schedule a free, virtual consultation to speak with our medical experts.
1 Arakawa R, Febres G, Cheng B, et al. Prospective study of gut hormone and metabolic changes after laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass. PLoS One 2020;15:e0236133.
2 Based on two validated questionnaires: DAILY-EATS and Weight Efficacy Lifestyle Questionnaire-Short Form (WEL-SF).